Icosavax (NASDAQ:ICVX) Earns Buy Rating from Analysts at Guggenheim

Guggenheim initiated coverage on shares of Icosavax (NASDAQ:ICVXFree Report) in a research report report published on Friday, MarketBeat.com reports. The brokerage issued a buy rating and a $28.00 target price on the stock.

Several other analysts have also recently weighed in on ICVX. William Blair reaffirmed an outperform rating on shares of Icosavax in a report on Wednesday, November 15th. Oppenheimer reaffirmed an outperform rating and issued a $25.00 target price on shares of Icosavax in a report on Monday, October 2nd.

Read Our Latest Research Report on Icosavax

Icosavax Stock Down 4.4 %

Shares of NASDAQ:ICVX opened at $10.75 on Friday. The firm’s 50 day moving average price is $7.35 and its 200 day moving average price is $8.28. The stock has a market cap of $538.47 million, a price-to-earnings ratio of -4.84 and a beta of 0.45. Icosavax has a fifty-two week low of $2.61 and a fifty-two week high of $16.45.

Institutional Trading of Icosavax

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. acquired a new stake in Icosavax during the third quarter worth approximately $29,000. Tower Research Capital LLC TRC raised its holdings in Icosavax by 716.5% during the third quarter. Tower Research Capital LLC TRC now owns 13,937 shares of the company’s stock worth $44,000 after purchasing an additional 12,230 shares in the last quarter. Barclays PLC raised its holdings in Icosavax by 505.6% during the fourth quarter. Barclays PLC now owns 6,020 shares of the company’s stock worth $47,000 after purchasing an additional 5,026 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Icosavax during the third quarter worth approximately $48,000. Finally, BNP Paribas Arbitrage SNC acquired a new stake in Icosavax during the third quarter worth approximately $60,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Icosavax Company Profile

(Get Free Report)

Icosavax, Inc, a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target.

See Also

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.